BioCentury
ARTICLE | Clinical News

biOasis preclinical data

February 18, 2013 8:00 AM UTC

In mice inoculated with a HER2-overespressing human breast cancer cell line that migrated to the brain and established brain tumors, twice-weekly subcutaneous BT2111 significantly reduced the mean number of HER2+ breast cancer tumors in the brain by 68% vs. untreated controls at day 35 (28 vs. 85 tumors, p<0.0001). BT2111 also significantly reduced the size of tumors remaining after treatment by 57% vs. untreated controls (p<0.0001). The active control Herceptin trastuzumab had no effect on reducing the number of tumors vs. untreated controls, but significantly reduced tumor size by 15% vs. untreated controls (p=0.03). BT2111 led to significant reductions on both endpoints compared to Herceptin (p<0.0001 for both). ...